An experimental Alzheimer’s drug has proven to slow cognitive and functional decline by 27%. Japanese drug maker, Eisai and its American partner, Biogen, explained the drug called Lecanemab, has met the first and second goal of the year and a half study. They stated the slowing of deterioration compared with a placebo was “highly statistically significant.” However, the trial results have yet to be reviewed by peers. The companies have already applied for the drug to be approved by the FDA. They agreed the results can serve as the confirmatory study to verify the clinical benefit of Lecanemab and the process will continue on.
Read the full article here